Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue

Endocrinology

Volumn 153, Issue 2, 2012, Pages 564-573

  Sangle, Ganesh V ^a   Lauffer, Lina M ^a,c   Grieco, Anthony ^a   Trivedi, Shivangi ^a   Iakoubov, Roman ^a,d   Brubaker, Patricia L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SITAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; FEMALE; HORMONE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; INTRACELLULAR SIGNALING; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ANIMALS, NEWBORN; CELL LINE; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IONOMYCIN; MICE; MOLECULAR STRUCTURE; PEPTIDES; PYRAZINES; RATS; RATS, WISTAR; TRIAZOLES; VENOMS;

EID: 84856088215     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1732     Document Type: Article

References (57)

1. Zimmet P, Alberti KG, Shaw J 2001 Global and societal implications of the diabetes epidemic. Nature 414:782-787 (Pubitemid 34000780)
2. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL 2007 Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399 (Pubitemid 351664540)
3. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
4. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM2008 Glucose sensing in L cells: a primary cell study. Cell Metab 8:532-539
5. Brubaker PL 2010 Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 151:1984-1989
6. Parker HE, Reimann F, Gribble FM 2010 Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 12:e1-e17
7. Brubaker PL, Drucker DJ 2004 Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145:2653-2659 (Pubitemid 38686211)
8. Kieffer TJ, McIntosh CH, Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
9. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ 1995 Both subcutaneously and intravenously administered glucagon like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131
10. Lovshin JA, Drucker DJ 2009 Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269
11. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE 2006 Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632-2637 (Pubitemid 44912190)
12. Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP 2008 Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on β-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 10:1212-1220
13. Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H 2011 Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract 65:154-164
14. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J 2008 A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glu- cagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149:2038-2047 (Pubitemid 351574507)
15. Lauffer LM, Iakoubov R, Brubaker PL 2009 GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:1058-1066
16. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K 2009 TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167-177
17. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49:2564-2571
18. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A 2007 Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30:217-223 (Pubitemid 46198322)
19. Rosenstock J, Sankoh S, List JF 2008 Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 10:376-386 (Pubitemid 351524285)
20. Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R 2007 Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 28:315-322 (Pubitemid 47439637)
21. Migoya EM, Miller JL, Gutierrez M, Zheng W, Johnson-Levonas AO, Liu Q, Matthews CZ, Wagner JA, Gottesdiener KM 2010 Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study. Clin Drug Invest 30:855-866
22. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA 2006 Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612-4619 (Pubitemid 44833446)
23. Bonner-Weir S, Trent DF, Honey RN, Weir GC 1981 Responses of neonatal rat islets to streptozotocin: limited B-cell regeneration and hyperglycemia. Diabetes 30:64-69 (Pubitemid 11022626)
24. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM 2006 Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290:E550-E559 (Pubitemid 43671703)
25. Wang Q, Brubaker PL 2002 Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263-1273
26. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL 1994 Activation of proglucagon gene transcription by protein kinase A in a novel mouse enteroendocrine cell line. Mol Endocrinol 8:1646-1655
27. Reimer RA, Darimont C, Gremlich S, Nicolas-Métral V, Rüegg UT, Macé K 2001 A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 142:4522-4528 (Pubitemid 32907084)
28. Anini Y, Brubaker PL 2003 Role of leptin in the regulation of glucagon- like peptide-1 secretion. Diabetes 52:252-259 (Pubitemid 36173176)
29. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL 2009 Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology 150:580-591
30. Iakoubov R, Izzo A, Yeung A, Whiteside CI, Brubaker PL 2007 Protein kinase Cζ is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology 148:1089-1098
31. Brubaker PL, Schloos J, Drucker DJ 1998 Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 139:4108-4114 (Pubitemid 28513695)
32. Anini Y, Brubaker PL 2003 Muscaranic receptors control glucagonlike peptide 1 secretion by human endocrine L cells. Endocrinology 144:3244-3250 (Pubitemid 36819927)
33. Edmondson SD, Mastracchio A, Mathvink RJ, He J, Harper B, Park YJ, Beconi M, Di Silvo J, Eiermann GJ, He H, Leiting B, Leone JF, Levorse DA, Lyons K, Patel RA, Patel SB, Petrov A, Scapin G, Shang J, Roy RS, Smith A, Wu JK, Xu S, Zhu B, Thornberry NA, Weber AE 2006 (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1- yl)-N,Ndimethyl- 4-oxo-2-(4-[1, 2,4]triazolo[1,5-a]-pyridin-6-ylphenyl) butanamide: a selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 49:3614-3627 (Pubitemid 43902466)
34. Reimer RA 2006 Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases. J Endocrinol 191:159-170 (Pubitemid 44756518)
35. Lim GE, Xu M, Sun J, Jin T, Brubaker PL 2009 The rho guanosine 5′-triphosphatase, cell division cycle 42, is required for insulin-induced actin remodeling and glucagon-like peptide-1 secretion in the intestinal endocrine L cell. Endocrinology 150:5249-5261
36. Deacon CF, Hughes TE, Holst JJ 1998 Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769 (Pubitemid 28201806)
37. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE 2005 (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl]- 1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151 (Pubitemid 40105255)
38. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB 2006 Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704 (Pubitemid 44324122)
39. Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA 2006 Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46:876-886 (Pubitemid 44050824)
40. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP 2008 Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 24: 489-496 (Pubitemid 351294398)
41. Patriti A, Aisa MC, Annetti C, Sidoni A, Galli F, Ferri I, Gullà N, Donini A 2007 How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery 142:74-85 (Pubitemid 47042093)
42. Cani PD, Hoste S, Guiot Y, Delzenne NM 2007 Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr 98:32-37 (Pubitemid 47272144)
43. Rindi G, Ratineau C, Ronco A, Candusso ME, Tsai M, Leiter AB 1999 Targeted ablation of secretin-producing cells in transgenic mice reveals a common differentiation pathway with multiple enteroendocrine cell lineages in the small intestine. Development 126: 4149-4156 (Pubitemid 29481571)
44. Ye DZ, Kaestner KH 2009 Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in mice. Gastroenterology 137:2052-2062
45. Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Cicotto S, Hora DF, Stearns RA, Vincent SH 2007 Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos 35:525-532 (Pubitemid 46513254)
46. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA 2007 The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 92:4165-4171 (Pubitemid 350074727)
47. Bock G, Dalla MC, Micheletto F, Basu R, Giesler PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C, Rizza RA, Vella A 2010 The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 73:189-196
48. Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T 2010 Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 12:323-333
49. Brubaker PL 1991 Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 128:3175-3182
50. Herman GA, Bergman A, Yi B, Kipnes M 2006 Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 22:1939-1947 (Pubitemid 44663399)
51. Bailey CJ 1992 Biguanides and NIDDM. Diabetes Care 15:755-772
52. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, Hue L, Andreelli F 2006 Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 574:41-53 (Pubitemid 43905795)
53. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G, Rotella CM 2001 Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24:489-494 (Pubitemid 32198418)
54. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I 2002 Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298:779-784 (Pubitemid 35356808)
55. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU 2002 Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 291:1302-1308 (Pubitemid 34694333)
56. Demuth HU, Hinke SA, Pederson RA, McIntosh CH 2002 Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective." Biochem Biophys Res Commun 296:229-232
57. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL 2011 Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L-cell. Endocrinology 152:4610-4619